Ahmad H. Awada
Advanced in Xeroderma Pigmentosum

Ahmad H. Awada

Brussels, BRU, BE 
Advanced in Xeroderma Pigmentosum
Brussels, BRU, BE 
OverviewLocationsClinical Research

Overview

Ahmad Awada practices in Brussels, Belgium. Mr. Awada is rated as an Advanced expert by MediFind in the treatment of Xeroderma Pigmentosum. His top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Febrile Neutropenia, Vulvectomy, and Hysterectomy.

His clinical research consists of co-authoring 387 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Xeroderma Pigmentosum.

Gender
Male

Locations

Brussels, BRU 1090, Belgium
Other Locations
Rue Meylemeersch 90, Anderlecht, BRU 1070, Belgium
Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Prospective Multicenter Open-label, Randomized Phase II Study of Pembrolizumab in Combination With Neoadjuvant EC-Paclitaxel Regimen in HER2-negative Inflammatory Breast Cancer.
A Prospective Multicenter Open-label, Randomized Phase II Study of Pembrolizumab in Combination With Neoadjuvant EC-Paclitaxel Regimen in HER2-negative Inflammatory Breast Cancer.
Enrollment Status: Active_not_recruiting
Publish Date: September 12, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab Injection, Neoadjuvant EC-Paclitaxel Chemotherapy
Study Phase: Phase 2
Phase II Prospective Imaging Study Evaluating the Utility of Pre-treatment zr89 Labelled Trastuzumab PET/CT and an Early FDG-PET/CT Response to Identify Patients With Advanced HER2+ BC Unlikely to Benefit From a Novel antiHER2 Therapy: TDM1
Phase II Prospective Imaging Study Evaluating the Utility of Pre-treatment zr89 Labelled Trastuzumab PET/CT and an Early FDG-PET/CT Response to Identify Patients With Advanced HER2+ BC Unlikely to Benefit From a Novel antiHER2 Therapy: TDM1
Enrollment Status: Completed
Publish Date: March 31, 2025
Intervention Type: Procedure, Drug
Study Drug: T-DM1
Study Phase: Phase 2
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase I/II Study of ARGX-110 in Patients With Advanced Malignancies Expressing CD70.
A Phase I/II Study of ARGX-110 in Patients With Advanced Malignancies Expressing CD70.
Enrollment Status: Completed
Publish Date: August 09, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: March 02, 2023
Intervention Type: Drug
Study Phase: Phase 2
Phase 1/2a Study to Evaluate the Safety, Activity, and Pharmacokinetics of Escalating Doses of GNS561 in Patients With Primary and Secondary Liver Cancer
Phase 1/2a Study to Evaluate the Safety, Activity, and Pharmacokinetics of Escalating Doses of GNS561 in Patients With Primary and Secondary Liver Cancer
Enrollment Status: Terminated
Publish Date: May 02, 2022
Intervention Type: Drug
Study Drug: GNS561
Study Phase: Phase 1/Phase 2
A Multi-national, Open-label, Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Administrations of NKR-2 in Patients With Different Metastatic Tumor Types (THINK - THerapeutic Immunotherapy With NKR-2)
A Multi-national, Open-label, Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Administrations of NKR-2 in Patients With Different Metastatic Tumor Types (THINK - THerapeutic Immunotherapy With NKR-2)
Enrollment Status: Unknown
Publish Date: September 19, 2019
Intervention Type: Biological
Study Drug: NKR-2 Cells
Study Phase: Phase 1/Phase 2
View 6 Less Clinical Trials

387 Total Publications

Xanthogranulomatous oophoritis: malignant appearance, benign pathology.
Xanthogranulomatous oophoritis: malignant appearance, benign pathology.
Journal: BMJ case reports
Published: November 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Awada's expertise for a condition
ConditionClose
View All 59 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile